Abstract:The concept of intrinsic efficacy has been enshrined in pharmacology for half of a century, yet recent data have revealed that many ligands can differentially activate signaling pathways mediated via a single G protein-coupled receptor in a manner that challenges the traditional definition of intrinsic efficacy. Some terms for this phenomenon include functional selectivity, agonist-directed trafficking, and biased agonism. At the extreme, functionally selective ligands may be both agonists and antagonists at different functions mediated by the same receptor. Data illustrating this phenomenon are presented from serotonin, opioid, dopamine, vasopressin, and adrenergic receptor systems. A variety of mechanisms may influence this apparently ubiquitous phenomenon. It may be initiated by differences in ligand-induced intermediate conformational states, as shown for the beta(2)-adrenergic receptor. Subsequent mechanisms that may play a role include diversity of G proteins, scaffolding and signaling partners, and receptor oligomers. Clearly, expanded research is needed to elucidate the proximal (e.g., how functionally selective ligands cause conformational changes that initiate differential signaling), intermediate (mechanisms that translate conformation changes into differential signaling), and distal mechanisms (differential effects on target tissue or organism). Besides the heuristically interesting nature of functional selectivity, there is a clear impact on drug discovery, because this mechanism raises the possibility of selecting or designing novel ligands that differentially activate only a subset of functions of a single receptor, thereby optimizing therapeutic action. It also may be timely to revise classic concepts in quantitative pharmacology and relevant pharmacological conventions to incorporate these new concepts.

Functional selectivity and dualsteric/bitopic GPCR targeting

Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.

Single Hormone or Synthetic Agonist Induces G S /G I Coupling Selectivity of EP Receptors Via Distinct Binding Modes and Propagating Paths

Progress on the development of Class A GPCR‐biased ligands

Functional Selectivity and Classical Concepts of Quantitative Pharmacology

Design of allosteric modulators that change GPCR G protein subtype selectivity

Functional consequences of spatial, temporal and ligand bias of G protein-coupled receptors

Angiotensin II cyclic analogs as tools to investigate AT1R biased signaling mechanisms

Molecular mechanism of biased signaling in a prototypical G protein–coupled receptor

Bivalent and bitopic ligands of the opioid receptors: The prospects of a dual approach

Discovery of GPCR ligands for probing signal transduction pathways

A bitopic agonist bound to the dopamine 3 receptor reveals a selectivity site

Design of bivalent ligands targeting putative GPCR dimers

Bivalent ligands targeting chemokine receptor dimerization: molecular design and functional studies.

Advances in Receptor Conformation Research: the Quest for Functionally Selective Conformations Focusing on the Β2-Adrenoceptor.

Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain.

Flipping the GPCR Switch: Structure-Based Development of Selective Cannabinoid Receptor 2 Inverse Agonists

Essential Dynamics of CB Receptor-Agonist Complexes: Implications for Signalling Bias

Highly biased agonism for GPCR ligands via nanobody tethering

Flavors of GPCR signaling bias

Angiotensin and biased analogs induce structurally distinct active conformations within a GPCR